Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.
Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...
After reaching a record high on optimism surrounding corporate growth under President-elect Donald Trump, all three major bourses lost momentum as sticky inflation and the Fed’s hawkish comments weighed...
Wall Street has shown a remarkable rally with the three major indices on track to wrap up the first nine months of 2024 near record highs. The artificial intelligence (AI) craze and rate-cut optimism have...
NetworkNewsWire Editorial Coverage : Global destigmatization, changing regulations and an upswing in research are speaking loudly to the opportunity for psychedelics to provide tangible improvements in...
/PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics...
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
On Sept. 16, the AdvisorShares Psychedelics ETF (NYSE Arca: PSIL) began trading. Its monumental because ...
The AdvisorShares® Psychedelics ETF has commenced trading under ticker NYSE: PSIL